

Synthesis, Spectroscopic Characterization and Antitumor Activity *in vitro* of Organometallo Substituted Polyoxotungstates (RM)₃P₂W₁₅O₅₉ⁿ⁻ (RM = CpTi, CpZr, C₄H₇O₂Sn or C₅H₉O₂Sn)

WANG, Xiao-Hong(王晓红) HE, Jiang-Hua(何江华) ZHANG, Rong-Chang(张荣昌)
LIU, Jing-Fu*(刘景福)

Department of Chemistry, Northeast Normal University, Changchun, Jilin 130024, China

Tetrabutylammonium or potassium salts of organometallic derivatives of lacunary polyanion (RM)₃P₂W₁₅O₅₉ⁿ⁻ (RM = CpTi, CpZr, C₄H₇O₂Sn or C₅H₉O₂Sn) have been prepared and structurally characterized by elemental analysis, IR, UV-vis, ¹H NMR and ¹⁸³W NMR spectroscopies. The title complexes exhibit antitumor activity *in vitro*.

Keywords organometallic derivative of polyoxometalate, Dawson structure, antitumor activity

Introduction

Polyoxometalates (POMs) are early transition metal oxygen anion clusters. Since the initial reports of the synthesis of [PW₁₁O₃₉{Ti(η⁵-C₅H₅)}]⁴⁻ 20 years ago, the fields of organometallic derivatives of POMs have expanded significantly, and these derivatives now form a full class of compounds.¹ This class of compounds has attracted much attention because of their variable applications, *e. g.* as industrial catalysts and potential antitumor drugs. There are only two or three papers involving the biological properties of organometallic derivatives of POMs. In order to develop this uncharted territory, the synthesis of organotin, organotitanium, organozirconium and organophosphory polyoxometalates, and their antitumor activity were investigated.²⁻¹¹ The reactivity of lacunary polyoxoanions with organometallic groups has also been summarized.¹ While the reaction of the trivacant lacunary polyoxoanion P₂W₁₅O₅₆¹²⁻ with organometallic groups has rarely been reported, except for [(PhSn)₃P₂W₁₅O₅₉]⁹⁻ and [(BuSn)₃P₂W₁₅O₅₉].⁹⁻¹² Herein, the synthesis, spectroscopic characterization and antitumor activity *in vitro* of cyclopentadienyltitanium, cyclopentadienylzirconium and estertin derivatives of [α-P₂W₁₅O₅₆]¹²⁻ polyanion have been reported.

Experimental

Preparation of the title compounds

Cp₂TiCl₂, Cp₂ZrCl₂, β-CH₃OOCCH₂CH₂SnCl₃ (C₄H₇-

O₂SnCl₃), β-CH₃OOCCH(CH₃)CH₂SnCl₃ (C₅H₉O₂SnCl₃) and Na₁₂[α-P₂W₁₅O₅₆]·24H₂O were prepared following the reported procedures.¹³⁻¹⁵ Their purity was checked by IR or ¹H NMR spectroscopies.

K₇H₂[(CpTi)₃P₂W₁₅O₅₉]·5H₂O (1) A solution containing Cp₂TiCl₂ (1.245 g, 5 mmol), acetylacetone (6 mmol) and water (30 mL) was stirred for 4 h to give a clear scarlet solution. Powdered Na₁₂[α-P₂W₁₅O₅₆]·24H₂O (1.7 mmol) was then added, and after vigorous stirring for 5 min the solution turned from red to yellow. The undissolved residue was filtered off and KCl was added to the filtrate in small portions until no more precipitation was observed. The resulting yellow solid was recrystallized from warm water and dried under suction. Yield 2.0 g (32%). Anal. calcd for K₇H₂[(CpTi)₃P₂W₁₅O₅₉]·5H₂O: C 3.96, H 0.38, K 6.11, P 1.38, Ti 3.21, W 61.73, H₂O 2.42; found C 4.00, H 0.37, K 6.29, P 1.36, Ti 3.11, W 61.39, H₂O 2.56.

(Bu₄N)₉[(CpZr)₃P₂W₁₅O₅₉] (2) (Bu₄N)₈Na₄[α-P₂W₁₅O₅₆] (1.0 g, 0.22 mmol) and (η⁵-C₅H₅)₂ZrCl₂ (0.194 g, 0.66 mmol) were dissolved in the mixture of 15 mL of CH₃CN and 70 mL of 1,2-C₂H₄Cl₂ to form a yellow solution. 2.0 g of anhydrous Na₂CO₃ was added. The resulting mixture was stirred vigorously until the yellow color disappeared. It was then filtered, and 200 mL of anhydrous ether were added to the filtrate to precipitate out the product. After pouring off the solvent, the product was redissolved in 100 mL of 1,2-C₂H₄Cl₂, reprecipitated by addition of ether and dried *in vacuo*. The crude product (1.93 g) was crystallized from (CH₃)₂COC₆H₅CH₃ to yield 1.45 g (33%) of product. Anal. calcd for (Bu₄N)₉[(CpZr)₃P₂W₁₅O₅₉]: C 29.79, H 5.24, N 1.97, P 0.97, W 43.02, Zr 4.27; found C 29.79, H 5.44, N 1.87, P 0.98, W 43.01, Zr 4.57.

K₄H₅[(CH₃OOCCH₂CH₂Sn)₃P₂W₁₅O₅₉]·10H₂O (3)

To a solution of CH₃COOCH₂CH₂SnCl₃ (0.94 g, 3 mmol) in H₂O (40 mL) was added solid Na₁₂P₂W₁₅O₅₆·24H₂O (4.5 g, 1 mmol) in small portions with stirring. The acidity of the mixture was adjusted to pH 4.5 with solid sodium acetate.

* E-mail: liujf513@nenu.edu.cn

Received June 4, 2002; revised September 23, 2002; accepted December 6, 2002.

Project supported by the National Natural Science Foundation of China (No. 20171011).

Table 2 ^1H NMR and ^{183}W NMR data

Complex	^1H NMR δ				^{183}W NMR δ^a			
	OMe	Me	β -H	α -H	Cp	"cap" W	"belt" W	"belt" W
1					6.53	-144.2(1)	-184.6(2)	-231.5(2)
2					6.57	-150.6(1)	-183.2(2)	-224.5(2)
3	3.74 (s)		3.00 (t)	1.72 (t)		-153.9(1)	-224.7(2)	-264.6(2)
4	5.22 (s)	4.20 (s)	3.31 (t)	1.83 (t)		-155.2(1)	-225.4(2)	-265.6(2)
$\text{C}_4\text{H}_7\text{O}_2\text{SnCl}_3$	3.94 (s)		2.94 (t)	2.22 (t)				

^a Relative intensity in parentheses.




Fig. 1 ^{183}W NMR spectra of complex **3** (a) and complex **1** (b).

The ^1H NMR spectra of compounds **1** and **2** display a $\eta^5\text{-C}_5\text{H}_5$ resonance at δ 6.53 and 6.57, respectively. The ^1H NMR spectra of estertin substituted polycomplexes are similar to those of $\text{C}_4\text{H}_7\text{O}_2\text{SnCl}_3$ and $\text{C}_5\text{H}_9\text{O}_2\text{SnCl}_3$, respectively. Only the chemical shifts changed, being affected by the polyanion. These results showed that the (CpTi) , (CpZr) or $(\text{RSn})^{3+}$ group incorporated with the trivalent

$\text{P}_2\text{W}_{15}\text{O}_{56}^{12-}$. The ^{183}W NMR spectra of the title complexes show three peaks with relative intensities 1:2:2, indicating that the title polyanions have the anticipated C_{3v} Dawson structure with three cap[WO] replaced by [RM], that is, the three substituted organometallic groups occupy the three polar vacant sites of $\text{P}_2\text{W}_{15}\text{O}_{56}^{12-}$ anion, forming $(\text{RM})_3\text{-P}_2\text{W}_{15}\text{O}_{59}^{9-}$ polyanions with Dawson structure.

Antitumor activity in vitro

The inhibitory effect and median inhibitory concentration (IC_{50}) against SSMC-7721 (liver cancer) and HeLa (cervix cancer) for the title complexes are given in Table 3.

The data summarized in Table 3 show that the title complexes display inhibitory action to two human cancer cells, and the degree of inhibitory of the polyoxometalate containing $[\text{CpTi}]^{3+}$ group is higher than those of others. This result was observed for the different lacunary heteropolyanions.^{4,17}

Table 3 Inhibitory effect and IC_{50} of the title complexes on two human tumor cells *in vitro*

Complex	Dose ($\mu\text{g}/\text{mL}$)	SSMC-7721		HeLa	
		Inhibitory effect (%)	IC_{50}^a ($\mu\text{g}/\text{mL}$)	Inhibitory effect (%)	IC_{50} ($\mu\text{g}/\text{mL}$)
1	100	100		79.6	
	10	24.7	20.8	109	47.2
	1	2.5		0.8	
2	100	97.1		78.2	
	10	13.8	40.6	12.6	63.3
	1	1		0.8	
3	100	100		100	
	10	16.9	30.6	9.6	50.1
4	100	100		100	
	10	17.1	30.1	11.3	48.3

^a The 50% inhibitory concentration (IC_{50}) is defined as the concentration which suppresses tumor cell by 50%.

References

- 1 Grouzerh, P.; Proust, A. *Chem. Rev.* **1998**, *98*, 77.
- 2 Wang, X. H.; Liu, J. F.; Cheng, Y. G.; Liu, J. T.; Pope, M. T. *Dalton* **2000**, 1139.
- 3 Sun, Z. G.; Liu, Q.; Liu, J. F. *Polyhedron* **2000**, *19*, 125.
- 4 Wang, X. H.; Dai, H. C.; Liu, J. F. *Polyhedron* **1999**, *18*, 2293.
- 5 Wang, X. H.; Dai, H. C.; Liu, J. F. *Trans. Met. Chem.* **1999**, *600*, 24.
- 6 Sun, Z. G.; Liu, Q.; Liu, J. F. *Trans Met. Chem.* **2000**, *25*, 374.
- 7 Sun, Z. G.; Liu, Q.; Liu, J. F. *Inorg. Chem. Commun.* **2000**, *3*, 328.
- 8 Wang, X. H.; Liu, J. T.; Li, J. X.; Liu, J. F. *Inorg. Chem. Commun.* **2001**, *4*, 372.
- 9 Sun, Z. G.; Liu, Q.; Liu, J. F. *Main Group Met. Chem.* **2000**, *23*, 189.
- 10 Sun, Z. G.; Liu, J. T.; Ma, J. F.; Liu, J. F. *Metal-Based Drugs* **2001**, *8*, 257.
- 11 Wang, X. H.; Sun, Z. G.; Liu, J. F. *Chin. J. Chem.* **1999**, *17*, 526.
- 12 Xin, F.; Pope, M. T. *Organometallics* **1994**, *13*, 4881.
- 13 Wilkinson, G.; Birmingham, J. M. *J. Am. Chem. Soc.* **1954**, *76*, 4281.
- 14 Hutten, R. E.; Burloy, J. W.; Oakes, V. *Organomet. Chem.* **1978**, *156*, 369.
- 15 Ginsberg, A. P. *Inorg. Synth.* **1992**, *27*, 168.
- 16 Knoth, W. H.; Domaille, P. J.; Farlee, R. D. *Organometallics* **1985**, *4*, 62.
- 17 Wang, X. H.; Liu, J. T.; Zhang, R. C.; Li, B.; Liu, J. F. *Main Group Met. Chem.* **2002**, *25*, 535.

(E0206045 LI, L. T.; ZHENG, G. C.)